Open access
Oct 2026
The role of CHIP and pre-treatment neutropenia in patients treated with chimeric antigen receptor T cells for hematological malignancies.
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in relapsed and refractory Bcell neoplasia but can cause immune-effector cell (IEC)-related toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic toxicity (ICAHT), and hemophagoc...
Andreas Riedel, Alisha Weiss-Haug, Britta Merz et al.
· Haematologica · 0 citations